Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.

Dittrich T, Benner A, Kimmich C, Siepen FAD, Veelken K, Kristen AV, Bochtler T, Katus HA, Müller-Tidow C, Hegenbart U, Schönland SO.

Haematologica. 2019 Jul;104(7):1451-1459. doi: 10.3324/haematol.2018.205336. Epub 2019 Jan 17.

2.

Deferred autologous stem cell transplantation in systemic AL amyloidosis.

Manwani R, Hegenbart U, Mahmood S, Sachchithanantham S, Kyriakou C, Yong K, Popat R, Rabin N, Whelan C, Dittrich T, Kimmich C, Hawkins P, Schönland S, Wechalekar A.

Blood Cancer J. 2018 Nov 5;8(11):101. doi: 10.1038/s41408-018-0137-9.

3.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO.

Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.

4.

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, Basset M, Müller-Tidow C, Bochtler T, Palladini G, Hegenbart U.

Blood. 2018 Nov 1;132(18):1988-1991. doi: 10.1182/blood-2018-04-845396. Epub 2018 Aug 14. No abstract available.

PMID:
30108065
5.

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.

Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, Hundemer M, Jauch A, Hegenbart U, Raab MS, Ho AD, Schönland S, Hose D.

Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018.

6.

MR neurography biomarkers to characterize peripheral neuropathy in AL amyloidosis.

Kollmer J, Weiler M, Purrucker J, Heiland S, Schönland SO, Hund E, Kimmich C, Hayes JM, Hilgenfeld T, Pham M, Bendszus M, Hegenbart U.

Neurology. 2018 Aug 14;91(7):e625-e634. doi: 10.1212/WNL.0000000000006002. Epub 2018 Jul 20.

PMID:
30030328
7.

First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival.

Pika T, Hegenbart U, Flodrova P, Maier B, Kimmich C, Schönland SO.

Blood. 2018 Jan 18;131(3):368-371. doi: 10.1182/blood-2017-09-806463. Epub 2017 Nov 27. No abstract available.

8.

Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools.

Kollmer J, Sahm F, Hegenbart U, Purrucker JC, Kimmich C, Schönland SO, Hund E, Heiland S, Hayes JM, Kristen AV, Röcken C, Pham M, Bendszus M, Weiler M.

Neurology. 2017 Aug 1;89(5):475-484. doi: 10.1212/WNL.0000000000004178. Epub 2017 Jul 5.

PMID:
28679600
9.

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, Ho AD, Hegenbart U, Schönland SO.

Blood. 2017 Aug 3;130(5):632-642. doi: 10.1182/blood-2017-02-767475. Epub 2017 May 26.

10.

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.

Haematologica. 2017 Aug;102(8):1424-1431. doi: 10.3324/haematol.2016.163246. Epub 2017 May 18.

11.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.

Milani P, Schönland S, Palladini G, Kimmich C, Basset M, Russo F, Foli A, Perlini S, Bochtler T, Ho AD, Merlini G, Hegenbart U.

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240. No abstract available.

PMID:
28434298
12.

Amyloid in bone marrow smears in systemic light-chain amyloidosis.

Kimmich C, Schönland S, Kräker S, Andrulis M, Ho AD, Mayer G, Dittrich T, Hundemer M, Hegenbart U.

Amyloid. 2017 Mar;24(1):52-59. doi: 10.1080/13506129.2017.1314959. Epub 2017 Apr 23.

PMID:
28434267
13.

Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.

Andrich K, Hegenbart U, Kimmich C, Kedia N, Bergen HR 3rd, Schönland S, Wanker E, Bieschke J.

J Biol Chem. 2017 Feb 10;292(6):2328-2344. doi: 10.1074/jbc.M116.750323. Epub 2016 Dec 28.

14.

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO.

Blood. 2016 Jul 28;128(4):594-602. doi: 10.1182/blood-2015-10-676361. Epub 2016 Jun 2.

15.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO.

J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.

PMID:
25779559
16.

In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.

Kollmer J, Hund E, Hornung B, Hegenbart U, Schönland SO, Kimmich C, Kristen AV, Purrucker J, Röcken C, Heiland S, Bendszus M, Pham M.

Brain. 2015 Mar;138(Pt 3):549-62. doi: 10.1093/brain/awu344. Epub 2014 Dec 18.

17.

A woman with a rare p.Glu74Gly transthyretin mutation presenting exclusively with a rapidly progressive neuropathy: a case report.

Schänzer A, Kimmich C, Röcken C, Haverkamp T, Weidner I, Acker T, Krämer HH.

J Med Case Rep. 2014 Dec 4;8:403. doi: 10.1186/1752-1947-8-403.

18.

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.

Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus Rosin M, Albertini R, Moratti R, Merlini G, Schönland S.

Blood. 2014 Oct 9;124(15):2325-32. doi: 10.1182/blood-2014-04-570010. Epub 2014 Aug 12.

19.

Joystick use for virtual power wheelchair driving in individuals with tremor: pilot study.

Dicianno BE, Sibenaller S, Kimmich C, Cooper RA, Pyo J.

J Rehabil Res Dev. 2009;46(2):269-75.

Supplemental Content

Loading ...
Support Center